| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H29N3OS |
| Molecular Weight | 395.561 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCNC(=O)C1=CC2=C(SC3=C(C=CC=C3)N2[C@H](C)CN4CCCC4)C=C1
InChI
InChIKey=KXMAIWXPZGQNCR-QGZVFWFLSA-N
InChI=1S/C23H29N3OS/c1-3-12-24-23(27)18-10-11-22-20(15-18)26(17(2)16-25-13-6-7-14-25)19-8-4-5-9-21(19)28-22/h4-5,8-11,15,17H,3,6-7,12-14,16H2,1-2H3,(H,24,27)/t17-/m1/s1
| Molecular Formula | C23H29N3OS |
| Molecular Weight | 395.561 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Pain: Twenty healthy male volunteers participated in a placebo-controlled, randomized, double-blind, five-way cross-over study. Single peroral doses of Apadoline (0.1, 0.5, and 1.0 mg), pentazocine (50 mg), and placebo were administered. Maximum antinociceptive effects were observed 2 h after the administration of 1.0 mg of Apadoline and 50 mg of pentazocine.
Route of Administration:
Oral
